- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about FDA Approval
Recent news which mentions FDA Approval
FDA Bans Vuse Menthol E-Cigs: Why Some Vapes Like Elf Bars Avoid Scrutiny, Others Don't
October 13, 2023
From Benzinga
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
February 03, 2023
From Benzinga
From Benzinga
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
From Benzinga
Spectrum Gets FDA Nod For Febrile Neutropenia Candidate, Sees Commercial Launch In Q4 2022
September 09, 2022
Tickers
SPPI
From Benzinga
Revance Shares Shoot Higher As FDA Cleared DAXXIFY Injection For Frown Lines
September 08, 2022
Tickers
RVNC
From Benzinga
Sanofi's Rare Disease Drug Xenpozyme Scores FDA Approval
September 01, 2022
Tickers
SNY
From Benzinga
Incyte Gets FDA Nod For Hematologic Malignancies Candidate
August 26, 2022
Tickers
INCY
From Benzinga
Bluebird Secures FDA Nod For Genetic Blood Disease Candidate
August 17, 2022
Tickers
BLUE
From Benzinga
Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August
July 29, 2022
Tickers
ARQT
From Benzinga
FDA Green Lights Ceruvia's Phase 2 Psilocybin Trial Program For Obsessive-Compulsive Disorder Treatment
June 29, 2022
From Benzinga
Cybin's Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder
June 28, 2022
Tickers
CYBN
From Benzinga
From Benzinga
Major Depressive Disorder Could Soon Have Treatment Option Via Cybin's Psilocybin Analog
May 31, 2022
Tickers
CYBN
From Benzinga
High Hopes For Alcohol Use Disorder Treatment: Clearmind's Successful Pre-IND Meeting With The FDA
May 26, 2022
Tickers
CMNDF
From Benzinga
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
January 11, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.